SEMA4D Antibody

What is SEMA4D and what key receptors mediate its biological functions?

SEMA4D (Semaphorin 4D, also known as CD100) is a 150-kDa transmembrane protein primarily expressed on lymphocytes and other immune cells. It belongs to the semaphorin family of proteins that were originally identified as axonal guidance factors but are now recognized to have pleiotropic functions.

SEMA4D interacts with three primary receptors with different binding affinities:

SEMA4D exists in both membrane-bound (150 kDa) and soluble forms (240 kDa). The soluble form is generated through proteolytic cleavage of the extracellular domain upon cell activation. Both forms are physiologically active, allowing SEMA4D to function as both a receptor and a ligand .

How do researchers typically validate SEMA4D antibody specificity?

Validating SEMA4D antibody specificity requires multiple complementary approaches to ensure reliable experimental outcomes:

• Western blot analysis with controls: Compare reactivity in known SEMA4D-expressing tissues (e.g., mouse/rat brain membranes, human lymphoid cell lines) with blocking peptide controls. Specific bands should appear at approximately 150 kDa (membrane form) or 240 kDa (soluble form), and disappear when pre-incubated with blocking peptides .

• Flow cytometry with SEMA4D knockout cells: Compare antibody binding between wild-type cells and SEMA4D knockout controls. The absence of binding in knockout cells confirms specificity .

• Immunoprecipitation: Validate by pulling down SEMA4D from cell lysates and confirming identity by mass spectrometry or western blotting with a different antibody targeting a distinct epitope.

• Immunohistochemistry: Confirm staining patterns in tissues known to express SEMA4D (lymphoid organs, brain) with appropriate positive and negative controls, including blocking peptides .

• Cross-reactivity testing: Evaluate binding to SEMA4D from multiple species if cross-reactivity is claimed. For example, the antibody VX15/2503 was validated against mouse, rat, rabbit, cynomolgus macaque, marmoset, rhesus macaque, and human SEMA4D .

What methodologies are recommended for measuring SEMA4D antibody binding affinity?

Several complementary methods are employed to accurately determine antibody-SEMA4D binding kinetics:

• Surface Plasmon Resonance (Biacore): This technique provides direct measurement of binding kinetics by immobilizing anti-species IgG (e.g., goat anti-mouse IgG Fc for murine antibodies or goat anti-human IgG Fc for humanized antibodies) on a chip, capturing the test antibody, and injecting recombinant SEMA4D at concentration ranges typically from 0-50 nM. Data is analyzed using global fitting to a 1:1 binding model to determine KD values. For example, VX15/2503 demonstrated KD values of 1.5 nM for mouse SEMA4D, 1.8 nM for rat, 3.9 nM for cynomolgus macaque, and 5.1 nM for human SEMA4D using this method .

• Flow cytometry-based cellular affinity assay: For measuring affinity to native cell-surface SEMA4D, researchers incubate cells (typically CD3+ T cells) with varying concentrations of anti-SEMA4D antibody, followed by fluorescently-labeled secondary antibody detection. Quantification beads (e.g., Quantum FITC MESF) are used to convert fluorescence intensity to molecules of equivalent soluble fluorochrome. Modified Scatchard analysis using nonlinear saturation analysis then calculates binding affinity. This method typically yields higher affinity values for cell-surface SEMA4D compared to recombinant protein (e.g., KD = 0.45 nM vs. 1-5 nM for VX15/2503) .

• Isothermal Titration Calorimetry (ITC): Though not explicitly mentioned in the search results, ITC provides thermodynamic parameters of binding (ΔH, ΔS) alongside affinity measurements, offering additional insights into binding mechanisms.

The discrepancy between affinities measured for recombinant versus native SEMA4D (1-5 nM vs. 0.45 nM for VX15/2503) suggests possible conformational differences between soluble and membrane-bound forms or differences in post-translational modifications that should be considered when interpreting results .

How can researchers effectively assess SEMA4D antibody blockade of receptor interactions?

Multiple experimental approaches can determine the functional blocking activity of anti-SEMA4D antibodies:

• Flow cytometry-based blocking assay: This method quantitatively measures an antibody's ability to prevent SEMA4D-receptor binding. The protocol involves:

  • Pre-incubating histidine-tagged SEMA4D with anti-SEMA4D antibodies at various concentrations

  • Adding the mixture to cells expressing SEMA4D receptors (e.g., 293.PLXNB1 cells)

  • Detecting bound SEMA4D using anti-His-APC antibodies

  • Analyzing by flow cytometry where decreased APC fluorescence indicates successful blocking

  • Calculating EC50 values using dose-response curves

  For VX15/2503, this assay yielded a mean EC50 of 1.2 nM, consistent with its affinity (KD) .

• Immunofluorescence visualization of blocking: This qualitative technique uses fluorescence microscopy to visualize SEMA4D-receptor interactions:

  • Plate receptor-expressing cells (e.g., 293.PLXNB1 or CHO.CD72)

  • Add recombinant SEMA4D-His alone or with blocking antibody

  • Detect bound SEMA4D with anti-His-APC

  • Counterstain nuclei with DAPI

  • Image using fluorescence microscopy

  This approach provides visual confirmation of blocking activity against different receptors .

• Functional cellular assays: These assess downstream biological effects of SEMA4D-receptor binding:

  • Cell collapse assay: Measures inhibition of SEMA4D-induced cytoskeletal reorganization

  • Migration assays: Evaluates impact on SEMA4D-induced cell motility

  • Signaling assays: Detects changes in receptor-mediated intracellular signaling cascades

For complete validation, researchers should demonstrate blocking against all three SEMA4D receptors (PLXNB1, PLXNB2, and CD72) as their relative importance may vary by experimental context .

What factors affect SEMA4D internalization following antibody binding and how can this be quantified?

SEMA4D internalization is an important pharmacodynamic parameter that influences antibody efficacy. Key considerations include:

Factors affecting internalization:

• Antibody isotype and Fc properties

• Epitope location relative to the cell membrane

• Cell type expressing SEMA4D

• Activation state of the cell

• Antibody concentration and exposure time

Quantification methods:

• Flow cytometry-based internalization assay:

  • Incubate cells with anti-SEMA4D antibody

  • Split samples into "quenched" and "non-quenched" groups

  • Treat quenched samples with anti-Ig antibodies that quench surface fluorescence

  • Compare fluorescence between quenched/non-quenched samples

  • Calculate percent internalization as the ratio of fluorescence in quenched vs. non-quenched samples

  Using this method, studies with VX15/2503 revealed that approximately 60% of SEMA4D internalized after 24 hours of antibody exposure in peripheral blood T cells .

• Fluorescence microscopy confirmation:

  • Perform similar antibody incubation as above

  • Fix and permeabilize cells

  • Add fluorescently labeled secondary antibodies

  • Counterstain with nuclear dyes and membrane markers

  • Visualize intracellular antibody-SEMA4D complexes

• ELISA for soluble SEMA4D: To distinguish between internalization and shedding:

  • Collect culture supernatants from antibody-treated cells

  • Measure total extracellular SEMA4D by ELISA

  • If levels decrease compared to controls, internalization is occurring

  • If levels increase, shedding is occurring

Studies with VX15/2503 demonstrated decreased SEMA4D in culture medium compared to controls, confirming internalization rather than shedding as the primary mechanism .

What approaches help distinguish between effects on membrane-bound versus soluble SEMA4D?

Differentiating the effects of antibodies on membrane-bound versus soluble SEMA4D is crucial for complete mechanistic understanding:

• Selective blocking experiments:

  • Pre-clear soluble SEMA4D from media before adding antibody (using immunoprecipitation)

  • Compare to experiments where recombinant soluble SEMA4D is added with antibody

  • This approach helps isolate effects on membrane-bound SEMA4D

• Differential detection assays:

  • Use ELISAs specific for total SEMA4D versus antibody-SEMA4D complexes

  • Monitor culture supernatants for changes in soluble SEMA4D levels

  • A decrease in soluble SEMA4D after antibody addition suggests internalization

  • An increase suggests enhanced shedding or stabilization of the soluble form

• Cell-based versus cell-free assays:

  • Compare antibody effects in cell culture systems (where both membrane and soluble forms exist)

  • Versus pure recombinant soluble SEMA4D systems

  • Differences suggest form-specific effects

• Specialized molecular techniques:

  • Generate cell lines expressing cleavage-resistant SEMA4D (by mutating protease sites)

  • Compare antibody effects on wild-type versus cleavage-resistant SEMA4D

  • This isolates effects on the membrane-bound form

Research with VX15/2503 demonstrated that cellular SEMA4D is internalized rather than shed following antibody exposure, suggesting that the antibody primarily acts by removing the membrane-bound form from circulation .

How does SEMA4D modulate the tumor microenvironment, and what mechanisms explain anti-SEMA4D antibody efficacy in cancer models?

SEMA4D plays complex roles in tumor biology through multiple mechanisms affecting immune, stromal, and tumor cells:

Key findings on SEMA4D's role in the tumor microenvironment:

• Barrier to immune infiltration: SEMA4D is highly expressed at the invasive tumor edge, creating a barrier that restricts immune cell access to tumors. Anti-SEMA4D antibodies disrupt this barrier, facilitating immune infiltration .

• Correlation with immune markers: Analysis across 34 cancer types revealed positive correlation between SEMA4D expression and infiltration of various immune cells, including follicular helper T cells (26/34 cancers), CD8+ T cells (25/34), M1 macrophages (23/34), M2 macrophages (28/34), and regulatory T cells (24/34) .

• Correlation with immune checkpoints: SEMA4D expression correlates significantly with multiple immune checkpoint molecules, including PD-1, PD-L1, CTLA4, TIM3, LAG3, and TIGIT, suggesting a role in T cell exhaustion .

• Relationship with tumor mutation burden (TMB) and microsatellite instability (MSI): SEMA4D expression negatively correlates with TMB in multiple cancer types (DLBC, KIRC, LGG, LIHC, LUSC, THCA, THYM) and with MSI in LIHC, MESO, PAAD, READ, SKCM, TGCT, and UCS, suggesting a role in suppressing neoantigen presentation .

Mechanisms of anti-SEMA4D antibody efficacy:

• Enhanced immune cell infiltration: Anti-SEMA4D antibodies increase tumor-infiltrating lymphocytes and activated monocytes in preclinical models by disrupting the SEMA4D barrier at tumor margins .

• Shift to pro-inflammatory tumor microenvironment: Treatment shifts the cytokine balance toward pro-inflammatory, anti-tumor responses .

• Synergy with other immunotherapies: Anti-SEMA4D antibodies significantly enhance the efficacy of immune checkpoint inhibitors (like anti-CTLA-4) through complementary immune-activating mechanisms .

• Reduction of T cell exhaustion: SEMA4D antibody treatment reduces expression of exhaustion markers (PD-1, LAG3, TIM3) on CD8+ T cells, potentially restoring anti-tumor activity .

The data from mouse models shows that SEMA4D expressed by tumor-infiltrating immune cells (89.62% ± 6.95% of immune cells in MC38 tumors and 52.09% ± 12.91% in B16 tumors) serves as a primary source of this immunomodulatory molecule in the tumor microenvironment .

What therapeutic potential do SEMA4D antibodies demonstrate in neurodegenerative disorders?

SEMA4D antibodies show promising therapeutic effects in various neurodegenerative conditions through several mechanisms:

Huntington's Disease (HD):

• Clinical evidence: The SIGNAL phase 2 trial evaluated pepinemab (VX15/2503, an anti-SEMA4D antibody) in early manifest (EM) and late prodromal (LP) Huntington's disease patients .

• While co-primary outcomes did not achieve statistical significance, secondary analyses showed:

  • Improvement in 6/6 components of the HD-CAB cognitive assessment battery in early manifest patients

  • Evidence that pepinemab crossed the blood-brain barrier and engaged its target

  • The antibody was generally well-tolerated in HD patients

Alzheimer's Disease (AD):

• Rationale: SEMA4D is highly expressed in brains of Alzheimer's patients, particularly in regions first affected by disease .

• Mechanism: SEMA4D upregulation in neurons under stress triggers activation of plexin-positive astrocytes, leading to loss of normal astrocyte functions .

• Current investigation: The SIGNAL-AD phase 1/2 study (NCT04381468) is evaluating pepinemab in early AD patients, assessing safety, brain metabolism (via FDG-PET), and cognition .

Rett Syndrome (Animal Model):

• Anti-SEMA4D treatment in Mecp2T158A/y mice (Rett syndrome model) demonstrated:

  • Improved motor coordination (increased latency to fall from rotarod)

  • Enhanced cognitive function (novel object recognition and elevated plus maze tests)

  • Normalized breathing patterns and reduced apneas

  • Effects were observed in both pre-symptomatic and symptomatic cohorts, suggesting both preventive and therapeutic potential

  • Dose-dependent effects were noted, with reduced efficacy when dosing frequency was decreased from twice weekly to once weekly

Proposed Mechanisms in Neurodegenerative Diseases:

• Prevention of astrocyte activation: By blocking SEMA4D binding to plexin receptors on astrocytes, the antibody helps maintain normal astrocyte function and morphology .

• Preservation of neurovascular unit integrity: Anti-SEMA4D protects endothelial tight junctions, potentially reducing inflammatory cell infiltration into the CNS .

• Regulation of oligodendrocyte responses: SEMA4D affects oligodendrocyte survival and remyelination processes, suggesting a role in preventing demyelination and promoting repair .

These findings suggest that anti-SEMA4D antibodies may represent a novel therapeutic approach for neurodegenerative conditions with potential disease-modifying effects beyond symptom management.

What methodological considerations are important when evaluating anti-SEMA4D antibodies in preclinical disease models?

When designing and interpreting preclinical studies of anti-SEMA4D antibodies, researchers should consider several methodological factors:

Animal Model Selection:

• Species cross-reactivity: Ensure the antibody binds to the species' SEMA4D with similar affinity as human SEMA4D. For instance, VX15/2503 was validated against mouse, rat, primate, and human SEMA4D with comparable binding affinities (KD range 1.5-5.1 nM) .

• Disease relevance: Choose models that recapitulate key aspects of the human disease:

  • For autoimmune conditions: Collagen-induced arthritis (CIA) mice for rheumatoid arthritis, experimental allergic encephalomyelitis (EAE) for multiple sclerosis

  • For cancer: Syngeneic models (e.g., Colon26, ERBB2+ mammary carcinoma) that maintain intact immune systems and tumor microenvironments

  • For neurodegenerative diseases: Transgenic models such as Mecp2T158A/y for Rett syndrome

Dosing Considerations:

• Dosing regimen optimization: The effects of anti-SEMA4D in Rett syndrome models showed dose-dependency, with reduced efficacy when dosing frequency was decreased from twice weekly to once weekly, highlighting the importance of dose optimization .

• Therapeutic vs. preventive protocols: Study designs should distinguish between:

  • Preventive treatment (starting before symptom onset)

  • Therapeutic treatment (initiating after symptoms are established)

  • Results may differ significantly between these approaches, as seen in the Rett syndrome model where both pre-symptomatic and symptomatic treatment showed benefits

Outcome Measures:

• Multidimensional assessment: Include multiple complementary endpoints:

  • For cancer: Tumor volume, survival, immune cell infiltration, cytokine profiles

  • For neurodegenerative disease: Motor function, cognitive tests, physiological measures (e.g., plethysmography for respiratory function), histopathology

  • For autoimmune disease: Clinical scores, histopathology scores for inflammation, pannus formation, cartilage/bone damage

• Translational biomarkers: Incorporate measures that can translate to clinical studies:

  • Imaging (PET, MRI) to assess target engagement or disease modification

  • Molecular markers that correlate with functional outcomes

Controls and Comparators:

• Appropriate antibody controls: Use isotype-matched control antibodies that lack SEMA4D binding.

• Standard-of-care comparisons: Include approved therapies as comparators (e.g., Enbrel in arthritis models), as was done in CIA studies where anti-SEMA4D showed comparable efficacy to etanercept .

• Combination assessments: Evaluate anti-SEMA4D alone and in combination with other therapies (e.g., immune checkpoint inhibitors in cancer models), which has demonstrated synergistic effects .

These methodological considerations are essential for generating robust preclinical data that can effectively guide clinical development strategies.

What epitope characteristics are important when developing therapeutic anti-SEMA4D antibodies?

Understanding the epitope characteristics of anti-SEMA4D antibodies is crucial for therapeutic development:

Key epitope considerations for anti-SEMA4D antibodies:

• Functional epitope mapping: The epitope of VX15/2503 was identified as a discontinuous, non-linear epitope comprised of three amino acid sequences within the SEMA domain: LKVPVFYALFTPQLNNV, KWTSFLKARLIASRP, and EFVFRVLIPRIARV. Further mapping suggested EFVFRVLIPRIARV as the most critical sequence .

• Strategic epitope location: The identified epitope of VX15/2503 is located in two functionally critical regions:

  • At the homodimerization interface of SEMA4D (important for semaphorin-plexin signaling)

  • At the binding interface between SEMA4D and PlexinB1

  This dual positioning allows the antibody to interfere with both SEMA4D homodimerization and receptor binding, potentially enhancing its therapeutic effects .

• Cross-species conservation: The epitope recognized by VX15/2503 is conserved across species (mouse, rat, primate, human), enabling accurate translation from preclinical to clinical studies. This conservation allowed studies in SEMA4D knockout mice to generate antibodies with broad species cross-reactivity .

• Conformation dependence: Evidence suggests the epitope is conformational rather than linear, as VX15/2503 does not detect SEMA4D in western blots under denaturing conditions. Advanced technologies like CLIPS epitope mapping can help characterize such conformational epitopes .

• Receptor selectivity considerations: Different epitopes may differentially affect binding to the three SEMA4D receptors (PLXNB1, PLXNB2, and CD72). In therapeutic development, screening for antibodies that block binding to specific receptors might enable more targeted interventions for particular disease settings.

Understanding these epitope characteristics can guide antibody engineering efforts to optimize therapeutic properties including affinity, selectivity, and effector functions.

How should researchers interpret conflicting data between in vitro and in vivo SEMA4D antibody studies?

Researchers often encounter discrepancies between in vitro and in vivo findings with SEMA4D antibodies. Several analytical frameworks can help reconcile these differences:

Sources of potential discrepancies:

• Complexity of SEMA4D biology:

  • In simplified in vitro systems, effects on single cell types or pathways are isolated

  • In vivo, the interplay between multiple cell types (immune, vascular, neural) creates complex networks of SEMA4D effects

  • Example: SEMA4D knockout mice show more pronounced immune defects than anti-SEMA4D antibody treatment in vivo, suggesting compensatory mechanisms operate in the intact organism

• Membrane-bound versus soluble SEMA4D dynamics:

  • Antibodies may affect the membrane-bound and soluble forms differently

  • Cellular systems that generate both forms may show different responses than recombinant protein systems

  • In vivo, the relative importance of each form may vary by tissue compartment or disease state

• Developmental versus acute interventions:

  • Genetic knockouts affect development from conception

  • Antibody interventions occur at defined timepoints in mature organisms

  • The SEMA4D literature notes: "the immune suppressive effects of SEMA4D blocking antibody in vivo are much less pronounced than reported for genetic deletion of SEMA4D in embryonic development"

Analytical approaches to reconcile discrepancies:

• Temporal analysis: Design studies that examine the time-course of anti-SEMA4D effects both in vitro and in vivo, as some processes (e.g., immune infiltration, neural remodeling) may require longer timeframes to manifest in vivo.

• Dose-response comparisons: Carefully analyze antibody concentrations required for effects in vitro versus achievable tissue concentrations in vivo. The Rett syndrome model showed dose-dependent effects, with reduced efficacy when dosing frequency decreased .

• Compartmental analysis: Examine tissue-specific effects of anti-SEMA4D treatment, as the antibody may distribute differently across tissue compartments in vivo.

• Compensatory mechanism assessment: Design experiments to identify potential compensatory pathways active in vivo but absent in vitro.

• Translation to human systems: When possible, validate findings in humanized models or using human samples to bridge the gap between preclinical and clinical observations.

By systematically addressing these factors, researchers can develop a more comprehensive understanding of anti-SEMA4D antibody effects across experimental systems.

What future directions might expand the therapeutic applications of SEMA4D antibodies?

Emerging research suggests several promising directions for expanding SEMA4D antibody applications:

Expansion of oncology applications:

• Combination immunotherapy strategies: Anti-SEMA4D antibodies show synergistic effects with immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1) in preclinical models, suggesting potential for enhancing current immunotherapies .

• Biomarker-guided patient selection: The correlation between SEMA4D expression and immune checkpoint molecules (PD-1, PD-L1, CTLA-4, TIM3, LAG3, TIGIT) suggests potential for identifying patients who might especially benefit from anti-SEMA4D therapy .

• Targeting the tumor microenvironment: SEMA4D's role in creating a barrier to immune infiltration at tumor margins represents a novel mechanism distinct from checkpoint inhibition, potentially addressing a major limitation of current immunotherapies .

Neurodegenerative disease applications:

• Additional neurodegenerative conditions: Beyond Huntington's and Alzheimer's disease, conditions with similar glial activation mechanisms might benefit from anti-SEMA4D therapy:

  • Parkinson's disease

  • Amyotrophic lateral sclerosis (ALS)

  • Multiple sclerosis (MS)

  • Traumatic brain injury

• Combination with disease-specific approaches: For example, combining anti-SEMA4D with amyloid-targeting therapies in Alzheimer's to address multiple disease mechanisms simultaneously .

• Neuroprotective applications: The ability of SEMA4D blockade to preserve integrity of the neurovascular unit suggests potential applications in stroke or other conditions involving blood-brain barrier disruption .

Autoimmune disease applications:

• Rheumatoid arthritis: Anti-SEMA4D demonstrated efficacy comparable to etanercept (Enbrel®) in reducing mean arthritic index and joint histology disease endpoints in collagen-induced arthritis models .

• Other autoimmune disorders: The immunomodulatory functions of SEMA4D suggest potential applications in:

  • Systemic lupus erythematosus

  • Inflammatory bowel disease

  • Psoriasis

Technical advancements:

• Bispecific antibody approaches: Developing bispecific antibodies targeting SEMA4D and complementary pathways (e.g., SEMA4D and PD-1) could enhance efficacy and specificity.

• Antibody-drug conjugates: Leveraging SEMA4D expression on specific cell populations for targeted delivery of therapeutic payloads.

• CNS delivery optimization: Enhancing blood-brain barrier penetration through antibody engineering could improve efficacy in neurodegenerative applications.

These expanding applications highlight the versatility of SEMA4D as a therapeutic target across multiple disease areas and suggest a broad horizon for future research and clinical development.

Comprehensive FAQs on SEMA4D Antibodies for Academic Researchers

What is SEMA4D and which receptors mediate its biological functions?

SEMA4D (Semaphorin 4D or CD100) is a 150-kDa transmembrane protein belonging to the semaphorin family. It exists as a disulfide-linked homodimer (300-kDa) on cell surfaces and can be released as a physiologically active 240-kDa soluble form (sSEMA4D) through proteolytic cleavage following cell activation .

SEMA4D interacts with three distinct receptors, each with different binding affinities and cellular distributions:

SEMA4D is expressed predominantly on lymphocytes (particularly T cells) and also on B cells, NK cells, monocytes, macrophages, and dendritic cells. Its expression is upregulated upon cellular activation, followed by shedding of the extracellular domain .

For research purposes, understanding the receptor-specific interactions is critical for designing targeted experiments and interpreting results in different physiological and pathological contexts.

What methodologies are recommended for validating SEMA4D antibody specificity?

Thorough validation of SEMA4D antibodies is essential for ensuring experimental reliability. Recommended methodological approaches include:

• Western blot analysis:

  • Compare reactivity with SEMA4D-expressing tissues (brain membranes, lymphoid cell lines)

  • Include blocking peptide controls to confirm specificity

  • Expect bands at approximately 150 kDa (membrane form) or 240 kDa (soluble form)

  • Note that conformational epitopes may not be detected under denaturing conditions

• Flow cytometry validation:

  • Test binding to SEMA4D-positive cells (T cells, B cells) versus negative controls

  • Compare staining patterns between wild-type and SEMA4D knockout cells when available

  • Confirm that cellular activation increases SEMA4D expression

• Immunoprecipitation:

  • Immunoprecipitate SEMA4D from cell lysates and confirm identity by western blotting

  • Use different antibodies recognizing distinct epitopes for confirmation

• Cross-species reactivity:

  • If cross-reactivity is claimed, systematically test against SEMA4D from each species

  • For example, VX15/2503 was validated against mouse, rat, rabbit, cynomolgus macaque, marmoset, rhesus macaque, and human SEMA4D

• Epitope mapping:

  • Identify the binding epitope using techniques such as CLIPS technology or alanine scanning

  • VX15/2503's epitope was mapped to three amino acid sequences within the SEMA domain that form a discontinuous conformational epitope

These validation steps should be performed prior to applying SEMA4D antibodies in more complex functional studies to avoid misinterpretation of results.

Binding Affinity Measurement:

• Surface Plasmon Resonance (Biacore):

  • Immobilize anti-species IgG (e.g., goat anti-human IgG Fc) on a CM5 sensor chip

  • Capture the anti-SEMA4D antibody

  • Inject recombinant SEMA4D at concentration ranges (typically 0-50 nM)

  • Analyze using BiaEvaluation software with global fitting to a 1:1 model

  • Example: VX15/2503 showed KD values of 1.5-5.1 nM across species

• Flow cytometry-based cellular affinity assay:

  • Incubate cells expressing native SEMA4D with varying antibody concentrations

  • Detect with fluorescently-labeled secondary antibody

  • Use Quantum MESF beads to convert fluorescence to absolute molecular units

  • Calculate KD using modified Scatchard analysis with nonlinear saturation analysis

  • This method often shows higher affinity for native SEMA4D (e.g., KD = 0.45 nM for VX15/2503)

Blocking Activity Assessment:

• Flow cytometry-based receptor binding assay:

  • Pre-incubate His-tagged SEMA4D with anti-SEMA4D antibodies at various concentrations

  • Add to receptor-expressing cells (e.g., 293.PLXNB1 cells)

  • Detect bound SEMA4D using anti-His-APC antibody

  • Analyze by flow cytometry where decreased fluorescence indicates blocking

  • Calculate EC50 values (mean EC50 for VX15/2503 is 1.2 nM)

• Immunofluorescence visualization:

  • Plate receptor-expressing cells (e.g., 293.PLXNB1 or CHO.CD72)

  • Add SEMA4D with or without blocking antibody

  • Detect bound SEMA4D and visualize by fluorescence microscopy

  • This provides qualitative evidence of blocking against different receptors

• Functional blocking assays:

  • Cell collapse assay: Measure inhibition of SEMA4D-induced cytoskeletal reorganization

  • Migration assays: Evaluate impact on SEMA4D-induced cell motility

  • Signaling assays: Detect changes in receptor-mediated signal transduction

For complete characterization, researchers should assess blocking activity against all three SEMA4D receptors (PLXNB1, PLXNB2, and CD72) as their relative importance varies by experimental context.

How does SEMA4D function in the tumor microenvironment, and what mechanisms explain anti-SEMA4D antibody efficacy in cancer models?

SEMA4D plays multifaceted roles in cancer biology through both direct effects on tumor cells and modulation of the tumor microenvironment (TME):

Expression patterns and correlations:

• SEMA4D is overexpressed in multiple cancers including head and neck, prostate, colon, breast, and lung cancers

• Expression at the invasive tumor edge creates a barrier to immune infiltration

• SEMA4D expression positively correlates with immune scores in 20 different tumor types

• Strong correlation with various immune cell infiltrates including follicular helper T cells, CD8+ T cells, macrophages, and regulatory T cells

Immunomodulatory mechanisms:

• Barrier to immune cell infiltration: SEMA4D at tumor margins restricts immune cell access; antibody blockade disrupts this barrier

• Regulation of T cell exhaustion: SEMA4D expression significantly correlates with exhaustion markers (PD-1, LAG3, TIM3, TIGIT) in multiple cancer types

• Association with immune checkpoints: SEMA4D expression correlates with 40+ immune checkpoint genes in 13 tumor types with the strongest correlations, suggesting coordinated immunosuppressive mechanisms

• Modification of myeloid cell function: Tumor-secreted SEMA4D stimulates myeloid-derived suppressor cell differentiation and enhances their immunosuppressive functions

• Relationship with tumor mutation burden: SEMA4D expression negatively correlates with TMB and microsatellite instability in multiple cancers, potentially reducing neoantigen presentation

Antibody efficacy mechanisms:

• Enhanced immune infiltration: Anti-SEMA4D antibodies facilitate access of immune cells into tumors by disrupting the SEMA4D barrier

• Alteration of TME composition: Treatment shifts the balance toward proinflammatory, antitumor immune responses

• Synergy with checkpoint inhibitors: Anti-SEMA4D shows synergistic activity with anti-CTLA-4 to promote complete tumor rejection and survival in preclinical models

• Source targeting: In mouse tumor models, 89.62% ± 6.95% and 52.09% ± 12.91% of immune cells in MC38 and B16 tumors respectively expressed SEMA4D, identifying immune cells as the primary SEMA4D source in the TME

These findings suggest anti-SEMA4D antibodies represent a distinct approach to cancer immunotherapy with complementary mechanisms to existing checkpoint inhibitors.

What is the therapeutic potential of SEMA4D antibodies in neurodegenerative disorders and what mechanisms underlie their effects?

SEMA4D antibodies show promising therapeutic potential across several neurodegenerative conditions through multiple mechanisms:

Huntington's Disease (HD):

• The SIGNAL phase 2 trial evaluated pepinemab (VX15/2503) in early manifest and late prodromal HD patients

• Although co-primary endpoints were not met, treatment showed benefits in multiple cognitive measures in early manifest patients

• Evidence confirmed pepinemab crossed the blood-brain barrier and engaged its target

Alzheimer's Disease (AD):

• SEMA4D is highly expressed in brains of Alzheimer's patients, especially in regions first affected by disease

• The ongoing SIGNAL-AD Phase 1/2 study (NCT04381468) is evaluating pepinemab in early AD, measuring safety, brain metabolism via FDG-PET, and cognition

Rett Syndrome:

• In a Mecp2^T158A/y mouse model, anti-SEMA4D treatment demonstrated:

  • Improved motor coordination on rotarod tests

  • Enhanced cognitive performance in object recognition tests

  • Normalized respiratory patterns and reduced apneas

  • Benefits in both pre-symptomatic and symptomatic animals

Underlying mechanisms:

• Modulation of astrocyte activation:

  • SEMA4D is upregulated in neurons under stress

  • It binds to plexin receptors on astrocytes, triggering their activation

  • Activated astrocytes lose normal supportive functions

  • Anti-SEMA4D antibodies block this pathway, preserving normal astrocyte function

• Preservation of neurovascular unit integrity:

  • SEMA4D blockade protects endothelial tight junctions

  • This maintains blood-brain barrier integrity

  • Restricted inflammatory cell infiltration into CNS

  • Reduced activation of astrocytes and microglia, processes implicated in various neurodegenerative diseases

• Effects on oligodendrocytes and myelination:

  • SEMA4D affects oligodendrocyte survival

  • Antibody blockade may preserve oligodendrocytes and promote remyelination

• Dose-dependent effects:

  • In the Rett syndrome model, reducing dosing frequency from twice weekly to once weekly decreased efficacy

  • This suggests the importance of maintaining adequate antibody concentrations for optimal therapeutic effect

These mechanisms position SEMA4D antibodies as potential disease-modifying therapies rather than merely symptomatic treatments for neurodegenerative disorders.

What methodological considerations are important when studying SEMA4D internalization following antibody binding?

Understanding SEMA4D internalization dynamics after antibody binding is crucial for characterizing pharmacodynamic properties and optimizing dosing strategies:

Key methodological considerations:

• Distinguishing internalization from shedding:

  • Both processes can reduce surface SEMA4D detection

  • Complementary approaches are required to differentiate between mechanisms:

    • Flow cytometry for surface expression changes

    • ELISA of culture supernatants for soluble SEMA4D

    • Microscopy for visualization of internalized complexes

  • With VX15/2503, decreased total sSEMA4D in culture medium confirmed internalization rather than shedding as the primary mechanism

• Quantification methods:

  • Flow cytometry with quenching:

    • Incubate cells with anti-SEMA4D antibody

    • Split samples and treat one set with anti-Ig antibodies to quench surface fluorescence

    • Calculate percent internalization from fluorescence ratio between quenched vs. non-quenched samples

    • VX15/2503 showed approximately 60% SEMA4D internalization in T cells after 24 hours

  • Fluorescence microscopy:

    • Enables direct visualization of internalized antibody-SEMA4D complexes

    • Allows co-localization with endocytic compartment markers

    • Provides qualitative confirmation of flow cytometry results

• Time course considerations:

  • Internalization is time-dependent, requiring measurement at multiple timepoints

  • With VX15/2503, maximum internalization (~60%) was observed after 24 hours

  • Shorter timepoints help characterize the kinetics of the process

• Cell type-specific differences:

  • Internalization rates may vary between different SEMA4D-expressing cells

  • T cells, B cells, and other SEMA4D-expressing cells should be compared

  • Similar internalization patterns were observed with VX15/2503 in human, rat, and cynomolgus macaque PBMCs

• Antibody isotype and epitope considerations:

  • Different antibody isotypes may affect internalization rates

  • Epitope location relative to the membrane can influence internalization dynamics

  • The VX15/2503 epitope in the SEMA domain was conducive to efficient internalization

Understanding these internalization dynamics helps predict in vivo pharmacodynamics, as internalization affects both the duration of target engagement and potential for antibody recycling through FcRn-mediated pathways.

How do anti-SEMA4D antibodies compare with other immunotherapeutic approaches in cancer, and what evidence supports combination strategies?

Anti-SEMA4D antibodies represent a distinct immunotherapeutic approach with both unique features and complementary mechanisms compared to established immunotherapies:

Mechanistic differentiation from other immunotherapies:

• Disruption of spatial barrier vs. molecular checkpoint release:

  • Anti-SEMA4D: Primarily works by disrupting the SEMA4D barrier at tumor margins that restricts immune cell access

  • Checkpoint inhibitors (anti-PD-1, anti-CTLA-4): Release intrinsic molecular brakes on T cell activation but don't address physical exclusion from tumors

• Effects on tumor microenvironment composition:

  • Anti-SEMA4D: Enhances recruitment of activated monocytes and lymphocytes into tumors and shifts the cytokine balance toward proinflammatory states

  • Other approaches like anti-CD40 or TLR agonists: Primarily activate existing immune cells without necessarily improving their infiltration

• Broad correlation with immune markers:

  • SEMA4D expression correlates positively with multiple immune checkpoints in 13 tumor types

  • This includes PD-1, PD-L1, CTLA-4, TIM3, LAG3, and TIGIT expression

  • Suggests SEMA4D may be part of a coordinated immunosuppressive program

Evidence supporting combination approaches:

• Synergy with checkpoint inhibitors:

  • Preclinical models show that anti-SEMA4D plus anti-CTLA-4 acts synergistically to promote complete tumor rejection and survival

  • The combination addresses complementary aspects of anti-tumor immunity:

    • SEMA4D antibody increases immune cell access to the tumor

    • Checkpoint inhibitors enhance the function of infiltrating T cells

• Correlation with checkpoint expression:

  • SEMA4D expression significantly correlates with PD-1 and PD-L1 expression in most tumor types

  • This correlation provides a molecular rationale for combining anti-SEMA4D with PD-1/PD-L1 inhibitors

• Effects on T cell exhaustion:

  • SEMA4D knockdown decreases PD-1, LAG3, and TIM3 expression in the tumor microenvironment

  • This suggests anti-SEMA4D may help overcome T cell exhaustion mechanisms that limit immunotherapy efficacy

• Compatibility with conventional therapies:

  • Anti-SEMA4D efficacy can be enhanced when combined with chemotherapy

  • This supports potential integration into standard-of-care regimens

These findings suggest that anti-SEMA4D antibodies may enhance the efficacy of existing immunotherapies by addressing a key limitation – inadequate immune cell infiltration into tumors – while potentially affecting additional immunosuppressive mechanisms in the tumor microenvironment.

How can researchers optimize epitope selection when developing therapeutic anti-SEMA4D antibodies?

Strategic epitope selection is critical for developing anti-SEMA4D antibodies with optimal therapeutic properties:

Critical epitope considerations:

• Functional domain targeting:

  • The SEMA domain contains the receptor-binding interfaces and is essential for biological activity

  • VX15/2503's epitope was mapped to three discontinuous sequences within the SEMA domain:

    • LKVPVFYALFTPQLNNV

    • KWTSFLKARLIASRP

    • EFVFRVLIPRIARV

  • Of these, EFVFRVLIPRIARV appeared most critical functionally

• Interference with critical protein interactions:

  • VX15/2503's epitope is strategically located at:

    • The homodimerization interface of SEMA4D (crucial for signaling)

    • The binding interface between SEMA4D and PlexinB1

  • This dual positioning allows the antibody to:

    • Interfere with SEMA4D homodimerization

    • Block receptor binding

• Conformational versus linear epitopes:

  • VX15/2503 recognizes a conformational epitope (does not detect denatured SEMA4D by western blot)

  • This requires specialized mapping techniques like CLIPS technology

  • Conformational epitopes often better represent the physiologically relevant protein state

• Cross-species conservation considerations:

  • For translational research, epitopes conserved across species are advantageous

  • VX15/2503's epitope is conserved in mouse, rat, primate, and human SEMA4D

  • This enables consistent interpretation between preclinical models and clinical studies

• Receptor-specific blocking:

  • Different epitopes may differentially affect binding to PLXNB1, PLXNB2, and CD72

  • In disease-specific contexts, selective blocking of particular receptor interactions may be desirable

  • Comprehensive assessment should determine blocking activity against all three receptors

• Shedding and internalization effects:

  • Epitope location can influence post-binding events like internalization

  • VX15/2503 binding leads to internalization (approximately 60% after 24 hours) rather than shedding

  • This effect can influence antibody pharmacokinetics and pharmacodynamics

• Therapeutic antibody development considerations:

  • Select epitopes amenable to humanization without loss of affinity

  • Avoiding epitopes in regions prone to polymorphism or post-translational modifications

  • Using SEMA4D knockout mice for immunization helps generate antibodies to conserved epitopes that may be masked by tolerance in wild-type mice

Careful epitope selection based on these considerations enhances the likelihood of developing antibodies with optimal therapeutic properties across different disease applications.

What factors should researchers consider when transitioning anti-SEMA4D antibodies from preclinical to clinical studies?

Successful translation of anti-SEMA4D antibodies from preclinical research to clinical development requires careful consideration of several factors:

Antibody characteristics and optimization:

• Species cross-reactivity:

  • Validate binding to SEMA4D from preclinical species and humans with similar affinity

  • VX15/2503 demonstrated comparable binding (KD 1.5-5.1 nM) across mouse, rat, cynomolgus macaque, and human SEMA4D

  • This enables consistent interpretation between animal studies and human trials

• Isotype selection for safety:

  • Choose isotypes that minimize unwanted effects (e.g., immune cell depletion)

  • VX15/2503 utilized a human IgG4 isotype to minimize potential depletion of SEMA4D-expressing immune cells

  • Confirm absence of CDC/ADCC activity in vitro using appropriate assays

• Antibody stability optimization:

  • For IgG4 antibodies, incorporate stabilizing mutations (e.g., S241P) to prevent half-antibody formation

  • Verify absence of bispecific antibody formation in vivo

Preclinical to clinical translation:

• Pharmacokinetic/pharmacodynamic relationships:

  • Establish dose-response relationships in preclinical models

  • The Rett syndrome model showed dose-dependent effects with reduced efficacy when dosing frequency decreased

  • Determine minimum effective concentration for target engagement

• Target engagement biomarkers:

  • Develop methods to confirm SEMA4D blockade in clinical samples

  • Consider receptor occupancy assays or downstream signaling markers

  • Evidence from the SIGNAL-HD trial confirmed pepinemab crossed the blood-brain barrier and engaged its target

• Patient selection strategies:

  • For cancer: Consider SEMA4D expression patterns and correlation with immune checkpoints

  • For neurodegenerative disease: Stage of disease may impact efficacy, as shown in Huntington's disease where early manifest patients showed more benefit

• Safety considerations:

  • Cytokine release risk:

    • VX15/2503 was tested with human PBMCs from 19 donors and showed no significant cytokine release compared to isotype control

    • This contrasts with antibodies like OKT3 (anti-CD3) that induced substantial cytokine release

  • Off-target binding:

    • GLP immunohistology studies assessed VX15/2503 reactivity with 33 human tissues

    • Binding was primarily to lymphoid cells with no significant off-target binding

• Endpoint selection:

  • Align preclinical endpoints with clinically relevant measures

  • For neurodegenerative diseases: cognitive assessments, functional measures, imaging (FDG-PET)

  • For cancer: objective response, immune infiltration, combination with standard therapies

• Clinical trial design:

  • Consider adaptive designs to optimize dosing and identify responding populations

  • The SIGNAL-HD study experience suggests focusing on early-stage disease and analyzing secondary endpoints to fully characterize treatment effects

These translational considerations help maximize the likelihood of successful clinical development and provide a framework for interpreting results across preclinical and clinical studies.

How should researchers reconcile differences between in vitro blocking assays and in vivo efficacy of anti-SEMA4D antibodies?

When reconciling differences between in vitro and in vivo findings with anti-SEMA4D antibodies, researchers should consider several explanatory frameworks:

Potential sources of discrepancy:

• Biological complexity differences:

  • In vitro systems isolate specific interactions (e.g., SEMA4D-PLXNB1 binding)

  • In vivo environments involve complex networks of cellular interactions

  • Example: SEMA4D knockout mice show more pronounced immune defects than anti-SEMA4D antibody treatment in vivo, suggesting compensatory mechanisms operate in intact organisms

• Membrane-bound vs. soluble SEMA4D dynamics:

  • Antibodies may differentially affect the 150-kDa membrane-bound form versus the 240-kDa soluble form

  • In vivo, the balance between these forms varies by tissue and disease state

  • VX15/2503 was shown to cause internalization rather than shedding of cellular SEMA4D

• Developmental vs. acute intervention differences:

  • "The immune suppressive effects of SEMA4D blocking antibody in vivo are much less pronounced than reported for genetic deletion of SEMA4D in embryonic development"

  • This highlights the importance of distinguishing between developmental requirements and acute signaling functions

Methodological approaches to reconcile discrepancies:

• Comprehensive blocking assessment:

  • Test blocking against all three SEMA4D receptors (PLXNB1, PLXNB2, CD72)

  • Measure both binding blockade and downstream functional effects

  • Example: VX15/2503 blocks SEMA4D binding to all three receptors and inhibits cellular consequences like cytoskeletal reorganization

• Tissue-specific analysis:

  • Examine antibody distribution and effects across different tissue compartments

  • Consider blood-brain barrier penetration for CNS applications

  • Analyze receptor expression patterns in target tissues

• Exposure-response correlation:

  • Measure antibody concentrations in target tissues

  • Correlate with functional outcomes to establish PK/PD relationships

  • The Rett syndrome model showed dose-dependent effects, with reduced efficacy when dosing frequency decreased

• Time-course considerations:

  • In vitro effects often measure immediate responses

  • In vivo efficacy may require sustained blockade or secondary adaptations

  • Design experiments with appropriate time points to capture delayed effects

• Combination with other approaches:

  • In cancer models, anti-SEMA4D showed enhanced efficacy when combined with checkpoint inhibitors

  • This suggests antibody effects may be context-dependent and synergistic with other interventions

By systematically addressing these factors, researchers can develop a more nuanced understanding of anti-SEMA4D antibody mechanisms and better predict in vivo efficacy from in vitro data.

What emerging applications of SEMA4D antibodies show promise beyond current research focus areas?

Anti-SEMA4D antibodies show promising potential across several emerging application areas beyond the current focus on cancer and neurodegenerative diseases:

Autoimmune and inflammatory conditions:

• Rheumatoid arthritis:

  • Anti-SEMA4D demonstrated efficacy comparable to etanercept (Enbrel®) in the collagen-induced arthritis mouse model

  • Treatment reduced clinical scores and inhibited disease progression

  • Histological improvements included reduced inflammation, pannus formation, and cartilage/bone damage

  • Multiple mechanisms may contribute: modulation of T cell responses, regulation of immune cell migration, and direct effects on osteoclast-osteoblast interactions

• Multiple sclerosis:

  • SEMA4D is elevated in MS patient sera (27.4 ng/ml vs. 10.4 ng/ml in healthy controls)

  • Anti-SEMA4D antibodies attenuate experimental allergic encephalomyelitis (EAE) in rodent models

  • Mechanisms include modulating the immune response to CNS antigens and affecting oligodendrocyte survival and remyelination

Vascular and cardiac applications:

• Neurovascular unit protection:

  • SEMA4D blockade preserves integrity of the neurovascular unit by protecting endothelial tight junctions

  • This suggests potential applications in stroke, traumatic brain injury, or other conditions with blood-brain barrier disruption

• Cardiovascular disease:

  • SEMA4D is expressed in the heart and on platelets, with expression increasing upon platelet activation

  • Anti-SEMA4D might affect cardiovascular remodeling processes or platelet-mediated inflammation

Rare diseases and genetic disorders:

• Rett syndrome:

  • Anti-SEMA4D therapy improved motor, cognitive, and respiratory function in a Mecp2^T158A/y mouse model

  • Effects observed in both pre-symptomatic and symptomatic animals

  • This suggests potential applications in other rare genetic disorders with neurological manifestations

Novel combination approaches:

• Bispecific antibody development:

  • Creating bispecific antibodies targeting SEMA4D and complementary pathways

  • For cancer: SEMA4D + PD-1 or SEMA4D + CTLA-4 bispecifics

  • For neurodegeneration: SEMA4D + targets involved in protein aggregation or neuroinflammation

• Combination with emerging therapeutic modalities:

  • RNA therapeutics: Combining anti-SEMA4D antibodies with siRNA targeting complementary pathways

  • Cell therapies: Enhancing CAR-T cell infiltration into solid tumors by disrupting the SEMA4D barrier

These emerging applications highlight the versatility of SEMA4D as a therapeutic target and suggest its relevance across multiple disease areas where immune dysregulation, cellular migration, or tissue architecture play pathogenic roles.

What are the current technical limitations in SEMA4D antibody research and how might they be addressed?

Despite significant advances, several technical challenges remain in SEMA4D antibody research. Addressing these limitations will enhance research quality and accelerate therapeutic development:

Current limitations and potential solutions:

• Detection of different SEMA4D forms:

  • Limitation: Distinguishing between membrane-bound (150 kDa) and soluble (240 kDa) SEMA4D in complex samples

  • Solutions:

    • Develop form-specific antibodies targeting cleavage site-specific epitopes

    • Establish multiplex assays that simultaneously measure both forms

    • Create reporter systems to monitor SEMA4D shedding in real-time

• Blood-brain barrier penetration:

  • Limitation: Limited CNS access restricts efficacy in neurodegenerative applications

  • Solutions:

    • Antibody engineering approaches (reduced size, increased lipophilicity)

    • Targeted delivery systems (nanoparticles, exosomes)

    • Alternative administration routes (intrathecal, intranasal)

    • The SIGNAL-HD trial demonstrated pepinemab does cross the BBB, but optimization may enhance CNS exposure

• Receptor-specific blocking:

  • Limitation: Current antibodies block all SEMA4D receptors without selectivity

  • Solutions:

    • Develop receptor-selective antibodies that preferentially block PLXNB1, PLXNB2, or CD72 interactions

    • Map interaction-specific epitopes at each receptor interface

    • Structure-guided antibody engineering to enhance selectivity

• Understanding cell type-specific effects:

  • Limitation: SEMA4D is expressed on multiple cell types with context-dependent functions

  • Solutions:

    • Single-cell analysis to characterize SEMA4D expression and signaling at cellular resolution

    • Cell type-specific knockout models to dissect functional contributions

    • TISCH database analysis revealed that SEMA4D is broadly expressed across immune cell types but particularly in CD8+ exhausted T cells

• Spatial distribution in complex tissues:

  • Limitation: Current methods provide limited insight into SEMA4D's spatial organization

  • Solutions:

    • Spatial transcriptomics to map SEMA4D expression patterns

    • Advanced imaging techniques (e.g., imaging mass cytometry)

    • The finding that SEMA4D creates a barrier at tumor margins highlights the importance of spatial information

• Translating between model systems:

  • Limitation: Discrepancies between in vitro, animal models, and human diseases

  • Solutions:

    • Humanized mouse models expressing human SEMA4D

    • Patient-derived organoids to test antibody effects in human tissues

    • Harmonized methodologies across species to enable direct comparisons

• Biomarker development:

  • Limitation: Lack of validated biomarkers for patient selection and response monitoring

  • Solutions:

    • Identify predictive biomarkers from existing clinical samples

    • Develop companion diagnostics for SEMA4D expression or activity

    • Explore correlations with other established biomarkers (e.g., PD-L1 expression, TMB)